Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Investig Med High Impact Case Rep ; 11: 23247096231193266, 2023.
Article in English | MEDLINE | ID: mdl-37596951

ABSTRACT

We present a case report of a 56-year-old woman who was diagnosed with biopsy-proven left thalamic glioblastoma multiforme (GBM). She was treated with standard concurrent chemotherapy and radiation, as well as a 2-year period of adjuvant temozolomide. She relapsed 2 ½ years after starting her initial therapy and was treated with bevacizumab and lomustine, but she relapsed. She was then placed on a phase 1/2 clinical trial that included KHK2455 and mogamulizumab-kpkc individually and in combination for almost 4 years. She had a rapid demise due to the development of a neutropenic pneumonia and treatment-induced acute myeloid leukemia (AML) and elected for hospice care.


Subject(s)
Brain Neoplasms , Glioblastoma , Leukemia, Myeloid, Acute , Female , Humans , Middle Aged , Glioblastoma/drug therapy , Temozolomide/therapeutic use , Lomustine/therapeutic use , Leukemia, Myeloid, Acute/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...